%PDF-1.4
%
1 0 obj
<<
/MarkInfo
<<
/Marked true
>>
/Metadata 3 0 R
/Outlines 4 0 R
/PageLayout/OneColumn
/Pages 5 0 R
/StructTreeRoot 6 0 R
/Type/Catalog
>>
endobj
2 0 obj
<<
/Author(CHMP)
/Comments(Template developed for European Medicines Agency by Fiona Lewis and Vanessa Crookes December 2009)
/Company(European Medicines Agency)
/CreationDate(D:20150216092543Z)
/Creator(Acrobat PDFMaker 10.1 for Word)
/DM_Authors()
/DM_Category(EPAR)
/DM_Creation_Date(23/01/2015 15:35:22)
/DM_Creator_Name(Mbaeliachi Nacho)
/DM_DocRefId(EMA/801521/2014)
/DM_Keywords()
/DM_Language()
/DM_Modifer_Name(Mbaeliachi Nacho)
/DM_Modified_Date(23/01/2015 15:35:22)
/DM_Modifier_Name(Mbaeliachi Nacho)
/DM_Modify_Date(23/01/2015 15:35:22)
/DM_Name(Sprycel_EPAR summary update II-43-G)
/DM_Owner(Castellani Federica)
/DM_Path(/01. Evaluation of Medicines/H-C/S-U/Sprycel-000709/05 Post Authorisation/EPAR/EPAR summary working area/07 Update II 43 G)
/DM_Status()
/DM_Subject(EPAR-EMA/496403/2010)
/DM_Title()
/DM_Type(emea_document)
/DM_Version(CURRENT,1.3)
/DM_emea_bcc()
/DM_emea_cc()
/DM_emea_doc_category(EPAR)
/DM_emea_doc_lang()
/DM_emea_doc_number(496403)
/DM_emea_doc_ref_id(EMA/801521/2014)
/DM_emea_filing_code( )
/DM_emea_from()
/DM_emea_internal_label(EMA)
/DM_emea_legal_date(nulldate)
/DM_emea_meeting_action()
/DM_emea_meeting_flags()
/DM_emea_meeting_hyperlink()
/DM_emea_meeting_ref()
/DM_emea_meeting_status()
/DM_emea_meeting_title()
/DM_emea_message_subject()
/DM_emea_received_date(nulldate)
/DM_emea_resp_body()
/DM_emea_revision_label()
/DM_emea_sent_date(nulldate)
/DM_emea_to()
/DM_emea_year(2010)
/Keywords(Sprycel, INN-dasatinib)
/ModDate(D:20180702150812+08'00')
/Producer(PDFsharp 1.32.2608-g \(www.pdfsharp.net\) \(Original: Adobe PDF Library 10.0\))
/SourceModified(D:20150216092527)
/Subject(EPAR)
/Title(Sprycel, INN-dasatinib)
>>
endobj
3 0 obj
<<
/Subtype/XML
/Type/Metadata
/Length 7108
>>
stream
2015-02-16T09:25:56Z
2015-02-16T09:25:43Z
2015-02-16T09:25:56Z
Acrobat PDFMaker 10.1 for Word
uuid:a4367aec-9d27-4edd-a886-45d397f0e6af
uuid:6ece1e7d-edca-4455-8097-13886c3074ff
3
application/pdf
Sprycel, INN-dasatinib
EPAR
CHMP
Sprycel
INN-dasatinib
Adobe PDF Library 10.0
Sprycel, INN-dasatinib
D:20150216092527
European Medicines Agency
Template developed for European Medicines Agency by Fiona Lewis and Vanessa Crookes December 2009
Castellani Federica
496403
nulldate
EPAR
EMA
nulldate
2010
nulldate
EPAR-EMA/496403/2010
CURRENT,1.3
Sprycel_EPAR summary update II-43-G
23/01/2015 15:35:22
23/01/2015 15:35:22
Mbaeliachi Nacho
Mbaeliachi Nacho
emea_document
EMA/801521/2014
EPAR
/01. Evaluation of Medicines/H-C/S-U/Sprycel-000709/05 Post Authorisation/EPAR/EPAR summary working area/07 Update II 43 G
EMA/801521/2014
Mbaeliachi Nacho
23/01/2015 15:35:22
EPAR-EMA/496403/2010
endstream
endobj
4 0 obj
<<
/Count 10
/First 7 0 R
/Last 8 0 R
/Type/Outlines
>>
endobj
5 0 obj
<<
/Count 3
/Kids[9 0 R 10 0 R 11 0 R]
/Type/Pages
>>
endobj
6 0 obj
<<
/K 12 0 R
/ParentTree 13 0 R
/ParentTreeNextKey 7
/RoleMap 14 0 R
/Type/StructTreeRoot
>>
endobj
7 0 obj
<<
/A 15 0 R
/Next 16 0 R
/Parent 4 0 R
/Title(What is Sprycel?)
>>
endobj
8 0 obj
<<
/A 17 0 R
/Parent 4 0 R
/Prev 18 0 R
/Title(Other information about Sprycel:)
>>
endobj
9 0 obj
<<
/Contents[19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 195 0 R]
/CropBox[0 0 595.32 841.92]
/Group 27 0 R
/MediaBox[0 0 595.32 841.92]
/Parent 5 0 R
/Resources
<<
/ColorSpace
<<
/CS0 28 0 R
/CS1 29 0 R
/CS2 30 0 R
/CS3 31 0 R
>>
/ExtGState
<<
/GS0 32 0 R
/GS1 196 0 R
>>
/Font
<<
/C2_0 33 0 R
/C2_1 34 0 R
/TT0 35 0 R
/TT1 36 0 R
/TT2 37 0 R
>>
/XObject
<<
/Im0 38 0 R
/Im1 39 0 R
>>
>>
/Rotate 0
/StructParents 0
/Type/Page
>>
endobj
10 0 obj
<<
/Contents[40 0 R 197 0 R]
/CropBox[0 0 595.32 841.92]
/MediaBox[0 0 595.32 841.92]
/Parent 5 0 R
/Resources
<<
/ColorSpace
<<
/CS0 30 0 R
>>
/Font
<<
/TT0 35 0 R
/TT1 36 0 R
>>
/ExtGState
<<
/GS0 196 0 R
>>
>>
/Rotate 0
/StructParents 1
/Type/Page
/Group
<<
/CS/DeviceRGB
/S/Transparency
/I false
/K false
>>
>>
endobj
11 0 obj
<<
/Annots 41 0 R
/Contents[42 0 R 198 0 R]
/CropBox[0 0 595.32 841.92]
/MediaBox[0 0 595.32 841.92]
/Parent 5 0 R
/Resources
<<
/ColorSpace
<<
/CS0 30 0 R
/CS1 29 0 R
>>
/Font
<<
/C2_0 34 0 R
/TT0 35 0 R
/TT1 36 0 R
/TT2 37 0 R
>>
/ExtGState
<<
/GS0 196 0 R
>>
>>
/Rotate 0
/StructParents 2
/Type/Page
/Group
<<
/CS/DeviceRGB
/S/Transparency
/I false
/K false
>>
>>
endobj
12 0 obj
<<
/K[43 0 R 44 0 R 45 0 R 46 0 R 47 0 R 48 0 R 49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R 70 0 R 71 0 R 72 0 R 73 0 R 74 0 R 75 0 R 76 0 R 77 0 R 78 0 R 79 0 R 80 0 R 81 0 R]
/P 6 0 R
/S/Sect
>>
endobj
13 0 obj
<<
/Nums[0 82 0 R 1 83 0 R 2 84 0 R 3 85 0 R 4 86 0 R 5 87 0 R 6 87 0 R]
>>
endobj
14 0 obj
<<
/Annotation/Span
/Body#20text#20#28Agency#29/P
/Chart/Figure
/Diagram/Figure
/Doc#20category#20heading#20#28Agency#29/P
/Doc#20subtitle#20#28Agency#29/P
/Doc#20title#20#28Agency#29/P
/DropCap/Figure
/Endnote/Note
/Footnote/Note
/Hyperlink/Span
/InlineShape/Figure
/No-num#20heading#203#20#28Agency#29/H3
/Outline/Span
/Ref.#20#28Agency#29/P
/Strikeout/Span
/Subscript/Span
/Superscript/Span
/TextBox/Art
/Underline/Span
>>
endobj
15 0 obj
<<
/D[9 0 R/XYZ 60 435 0]
/S/GoTo
>>
endobj
16 0 obj
<<
/A 88 0 R
/Next 89 0 R
/Parent 4 0 R
/Prev 7 0 R
/Title(What is Sprycel used for?)
>>
endobj
17 0 obj
<<
/D[11 0 R/XYZ 60 335 0]
/S/GoTo
>>
endobj
18 0 obj
<<
/A 90 0 R
/Next 8 0 R
/Parent 4 0 R
/Prev 91 0 R
/Title(What measures are being taken to ensure the safe and effective use of Sprycel?)
>>
endobj
19 0 obj
<<
/Filter/FlateDecode
/Length 625
>>
stream
xŕN@)r}ΞWBH$ГZ +."T&T$`Tx:9m6Xf~OnYq0o&a^q4jtoE-"1^MAPl_ǛFË}:^NffR`wv˖yVx@)D@"Xh_TKcDA31i`g/ϳ;ՔkvBWdE)m
pWXQt2cDtDmd
)㐕QɎ>Q9O)ثEAXh-L0Au{BHp^
gb\)}Q
YIG,X#m:5ɤB+H#xRHI,1Rې!$YUk~n,W5g9:~C
C:jf?2(k/ɚ䦏[f/t&Q
N=F&K(T:wʅC|r,Dt>q._1
aEĘƁ_Il# 4
o:lk
+:3ah'Rs0-7!+mNB[iw`S&?]6_:
endstream
endobj
20 0 obj
<<
/Filter/FlateDecode
/Length 610
>>
stream
xTj0}ẈDvFe JP>8CV˦,RXbA9:s!h/T!AP,W mJ.kQ՝h